Physician profile
John Leone
NPI 1871558825
$6,361.10
in general payments reported to CMS, 2019-2025
37 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $182 · 2022: $999 · 2023: $1,430 · 2024: $1,278 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,086.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $725.37 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $566.14 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $552.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $403.20 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $333.56 | 2019-2025 | |
| Exact Sciences Corporation | $255.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $220.67 | 2019-2023 | |
| Glaxosmithkline, LLC. | $215.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $210.85 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.31 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $176.69 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $155.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $144.87 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $112.73 | 2019-2025 | Eliquis, Camzyos |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Leone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.